No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

MLA

Hollestelle, Antoinette, et al. “No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer.” Gynecologic Oncology, vol. 141, no. 2, May 2016, pp. 386–401. EBSCOhost, https://doi.org/10.1016/j.ygyno.2015.04.034.

APA

Hollestelle, A., van der Baan, F. H., Berchuck, A., Johnatty, S. E., Aben, K. K., Agnarsson, B. A., Aittomäki, K., Alducci, E., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Antoniou, A. C., Apicella, C., Arndt, V., Arnold, N., Arun, B. K., Arver, B., Ashworth, A., Baglietto, L., … Goode, E. L. (2016). No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 141(2), 386–401. https://doi.org/10.1016/j.ygyno.2015.04.034

Chicago

Hollestelle, Antoinette, Frederieke H van der Baan, Andrew Berchuck, Sharon E Johnatty, Katja K Aben, Bjarni A Agnarsson, Kristiina Aittomäki, et al. 2016. “No Clinical Utility of KRAS Variant Rs61764370 for Ovarian or Breast Cancer.” Gynecologic Oncology 141 (2): 386–401. doi:10.1016/j.ygyno.2015.04.034.